Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 10Recruiting 5Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 40Lymphoid 32Other hematologic neoplasm 15CNS 12Genitourinary 8Other solid neoplasm 7Endocrine 5Gynecologic 4Plasma cell 3Sarcoma 2Myeloid 2NET 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Neuroendocrine 3Neuroendocrine Tumors 1Neuroendocrine Neoplasms 1Gastrointestinal Neoplasms 1Adrenocortical Carcinoma 1

Interventions

lutetium Lu 177 dotatate 16Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 9Specimen Handling 8Everolimus 8pembrolizumab 7cabozantinib 6Cisplatin 6fluorodopa F 18 5Etoposide 5trametinib 4surufatinib 4lanreotide 4dabrafenib 4cemiplimab 4X-Rays 4Temozolomide 4Nivolumab 4Lutetium-177 4Lutetium 4Fluorodeoxyglucose F18 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3lenvatinib 3copper dotatate CU-64 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Surveys and Questionnaires 3Somatostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Etoposide × Endocrine × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

NCT04268121 2025-07-23

NEONEC

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Recruiting
78 enrolled
EndocrineGastrointestinal

Gastrointestinal Neoplasms, Carcinoma, Neuroendocrine

NCT05913427 2024-08-01

PESETA

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Phase 2 Recruiting
80 enrolled
Endocrine

Adrenocortical Carcinoma

NCT06372626 2024-06-14

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Recruiting
93 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡